174 related articles for article (PubMed ID: 15351976)
1. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.
Cavalcanti GB; Vasconcelos FC; Pinto de Faria G; Scheiner MA; de Almeida Dobbin J; Klumb CE; Maia RC
Cytometry B Clin Cytom; 2004 Sep; 61(1):1-8. PubMed ID: 15351976
[TBL] [Abstract][Full Text] [Related]
2. P53 protein expression in human leukemia and lymphoma cells.
Koníková E; Kusenda J
Neoplasma; 2001; 48(4):290-8. PubMed ID: 11712681
[TBL] [Abstract][Full Text] [Related]
3. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
Maslak P; Hegewisch-Becker S; Godfrey L; Andreeff M
Cytometry; 1994 Sep; 17(1):84-93. PubMed ID: 8001461
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia.
Nakagawa Y; Yamaguchi S; Hasegawa M; Nemoto T; Inoue M; Suzuki K; Hirokawa K; Kitagawa M
Leuk Res; 2004 May; 28(5):487-94. PubMed ID: 15068902
[TBL] [Abstract][Full Text] [Related]
8. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay.
Lamy T; Drenou B; Grulois I; Fardel O; Jacquelinet C; Goasguen J; Dauriac C; Amiot L; Bernard M; Fauchet R
Leukemia; 1995 Sep; 9(9):1549-55. PubMed ID: 7658724
[TBL] [Abstract][Full Text] [Related]
9. p53 flow cytometry evaluation in leukemias: correlation to factors affecting clinical outcome.
Cavalcanti GB; Scheiner MA; Simões Magluta EP; Vasconcelos FC; Klumb CE; Maia RC
Cytometry B Clin Cytom; 2010 Jul; 78(4):253-9. PubMed ID: 20198607
[TBL] [Abstract][Full Text] [Related]
10. Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells.
Lawrence HJ; Sauvageau G; Ahmadi N; Lopez AR; LeBeau MM; Link M; Humphries K; Largman C
Exp Hematol; 1995 Oct; 23(11):1160-6. PubMed ID: 7556525
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
Giles FJ; Kantarjian HM; Cortes J; Thomas DA; Talpaz M; Manshouri T; Albitar M
Cancer; 1999 Sep; 86(5):805-13. PubMed ID: 10463979
[TBL] [Abstract][Full Text] [Related]
13. Expression of programmed cell death proteins in patients with chronic myeloid leukemia.
Strnad M; Brajuskovic G; Strelic N; Todoric-Zivanovic B; Stamatovic D; Tatomirovic Z; Magic Z
J BUON; 2008; 13(3):403-8. PubMed ID: 18979557
[TBL] [Abstract][Full Text] [Related]
14. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells.
Suárez L; Vidriales MB; Moreno MJ; López A; García-Laraña J; Pérez-López C; Tormo M; Lavilla E; López-Berges MC; de Santiago M; San Miguel JF; Orfao A;
Haematologica; 2005 Jan; 90(1):54-9. PubMed ID: 15642669
[TBL] [Abstract][Full Text] [Related]
15. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
Okabe M
Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
[TBL] [Abstract][Full Text] [Related]
16. Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice.
Vasconcelos FC; Cavalcanti GB; Silva KL; de Meis E; Kwee JK; Rumjanek VM; Maia RC
Leuk Res; 2007 Apr; 31(4):445-54. PubMed ID: 16979236
[TBL] [Abstract][Full Text] [Related]
17. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
Iolascon A; Della Ragione F; Giordani L; Serra A; Saglio G; Faienza MF
Haematologica; 1998 Sep; 83(9):771-7. PubMed ID: 9825572
[TBL] [Abstract][Full Text] [Related]
18. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
[TBL] [Abstract][Full Text] [Related]
19. [Rearrangement and expression of bcr-abl genes in CML and ALL].
Kunieda Y; Okabe M
Rinsho Ketsueki; 1991 Jun; 32(6):623-8. PubMed ID: 1890738
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
Carulli G; Petrini M; Marini A; Vaglini F; Caracciolo F; Grassi B
Haematologica; 1990; 75(6):516-21. PubMed ID: 1982999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
